Statement: the primary trial recorded a patient with chest pain, whereas the secondary trial observed a patient with abdominal pain.
Primary_evidence: Adverse Events 1:   Total: 45/298 (15.10%)   Febrile neutropenia * 10/298 (3.36%)   Neutropenia * 9/298 (3.02%)   Leukopenia * 0/298 (0.00%)   Thrombocytopenia * 0/298 (0.00%)   Lymphadenopathy * 1/298 (0.34%)   Cardiac failure congestive * 0/298 (0.00%)   Arrhythmia * 0/298 (0.00%)   Myocardial infarction * 1/298 (0.34%)   Angina pectoris * 1/298 (0.34%)   Atrial fibrillation * 0/298 (0.00%) Adverse Events 2:   Total: 65/297 (21.89%)   Febrile neutropenia * 13/297 (4.38%)   Neutropenia * 7/297 (2.36%)   Leukopenia * 1/297 (0.34%)   Thrombocytopenia * 1/297 (0.34%)   Lymphadenopathy * 0/297 (0.00%)   Cardiac failure congestive * 2/297 (0.67%)   Arrhythmia * 1/297 (0.34%)   Myocardial infarction * 1/297 (0.34%)   Angina pectoris * 0/297 (0.00%)   Atrial fibrillation * 1/297 (0.34%)
Secondary_evidence: Adverse Events 1:   Total: 2/38 (5.26%)   Febrile neutropenia 0/38 (0.00%)   Abdominal pain 1/38 (2.63%)   Skin infection 0/38 (0.00%)   Seizure 1/38 (2.63%)